196707-32-1

Usage

Chemical Properties

white powder

InChI:InChI=1/C13H16FNO4/c1-13(2,3)19-12(18)15-10(11(16)17)8-4-6-9(14)7-5-8/h4-7,10H,1-3H3,(H,15,18)(H,16,17)/p-1/t10-/m1/s1

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 93939-74-3 (R)-2-(4-fluorophenyl)glycine 
• 351-95-1 N-(4-fluoro-phenyl)-glycine 
• 153903-23-2 (4-fluorobenzyl)carbamic acid tert-butyl ester 
• 140-75-0 para-fluorobenzylamine 
• 124-38-9 carbon dioxide 
• 196707-30-9 N-(trimethylsilyl)-N-(tert-butyloxycarbonyl)-4-fluorobenzylamine 

Downstream Products

• 1001413-74-6 [(R)-1-(4-fluorophenyl)-2-hydroxyethyl]carbamic acid tert-butyl ester 
• 170902-76-8 methyl (R)-amino-(4-fluorophenyl)-acetate 
• 1227811-15-5 (S)-prop-2-ynyl 2-(tert-butoxycarbonylamino)-2-(4-fluorophenyl)acetate 
• 1443764-09-7 tert-butyl [(1R)-1-(4-fluorophenyl)-2-{[4-(2-{[2-methoxy-4-(methylsulfonyl)phenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl]amino}-2-oxoethyl]carbamate 

Relevant academic research and scientific papers

PIPERAZINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT

The present inventions relate to substituted piperazine derivatives of general formula (I) and to the manufacture of said compounds, pharmaceutical compositions comprising a compound according to general formula (I), and the use of said compounds for the treatment of various medical conditions related to glycine transporter-1 (GlyT1).

Piperazine derivatives and the use thereof as medicament

The present inventions relate to substituted piperazine derivatives of general formula (I) and to the manufacture of said compounds, pharmaceutical compositions comprising a compound according to general formula (I), and the use of said compounds for the treatment of various medical conditions related to glycine transporter-1 (GlyT1).

Rapid access to N-Boc phenylglycine derivatives via benzylic lithiation reactions

We report a novel and efficient method for the enantioselective synthesis of N-Boc protected phenylglycines. Yields and enantiomeric ratios vary widely depending on the nature of the solvent, the substrate and on the method of forming the chiral complex. Results show that the major reaction pathway is an enantioselective deprotonation/substitution process. The enantioselectivity appears to be limited by the chiral discrimination ability of the s-BuLi-(-)-sparteine complex. The synthetic method described is one of the shortest route to useful enantioenriched N-Boc phenylglycine derivatives.

Enantioselective synthesis of phenylglycines using (-) sparteines·s-BuLi complex

The enantioselective synthesis of N-t-Boc protected phenylglycine derivatives is reported. The synthetic strategy involved the enantioselective deprotonation of N-t-Boc-N-TMS protected benzylamines using the (-) sparteine·s-BuLi complex.